IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas

被引：0
|
作者：
Li, K. [1 ]
Kotturi, M. F. [2 ]
Manlusoc, M. [3 ]
Yun, R. [1 ]
Hinton, P. R. [1 ]
Logronio, K. [2 ]
Baliga, R. [4 ]
Hernandez, G. [5 ]
Sinclair, A. M. [3 ]
Carroll, S. F. [2 ]
Godfrey, W. R. [6 ]
Keyt, B. A. [7 ]
机构：
[1] IGM Biosci, Antibody Discovery, Mountain View, CA USA
[2] IGM Biosci, Preclin Sci, Mountain View, CA USA
[3] IGM Biosci, Immunooncol, Mountain View, CA USA
[4] IGM Biosci, Discovery Biol, Mountain View, CA USA
[5] IGM Biosci, Clin Biomarkers, Mountain View, CA USA
[6] IGM Biosci, Clin Dev Clin Stats & Regulatory, Mountain View, CA USA
[7] IGM Biosci, Res & Dev, Mountain View, CA USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.134
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
841P
引用
收藏
页码：S778 / S779
页数：2
相关论文
共 50 条
  • [41] A novel CD20/CD3 T cell engager designed from Rituximab targeting CD20+cancer with multiple mechanisms.
    Cai, Wenyan
    Dong, Jianbo
    Kankanamalage, Sachith Gallolu
    Titong, Allison
    Shi, Jiadong
    Jia, Zhejun
    Wang, Bo
    Huang, Cai
    Zhang, Jing
    Lin, Jun
    Kan, Steven Z.
    Zhou, Joe
    Liu, Yuc
    CANCER RESEARCH, 2021, 81 (13)
  • [42] First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy.
    Brownstein, Carrie M.
    Adriaens, Lieve
    Bannerji, Rajat
    Chavez, Julio C.
    Levy, Ronald
    Ansell, Stephen Maxted
    Advani, Ranjana H.
    Patel, Snehal
    Kostic, Ana
    Trail, Pamela
    Lowy, Israel
    Kohrt, Holbrook Edwin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting
    Sun, Hao
    Xing, Haizhou
    Han, Lijie
    Song, Yongping
    Jiang, Zhongxing
    Liu, Yanyan
    Yu, Jifeng
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (05) : 321 - 326
  • [44] JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models
    Fontan, Lorena
    Zwolak, Adam
    Guimerans-Lorenzo, Irene
    Bekkers, Mariette
    Hein, Nicholas
    Vloemans, Nele
    Trella, Emanuele
    Smets, Tina
    Cornelissen, Ivo
    Assefa, Alemu
    Verbist, Bie
    Amorim, Ricardo
    Seth, Pankaj
    Dash, Ranjeet Prasad
    Luistro, Leopoldo
    Mattson, Bethany
    Dragovich, Matthew A.
    Hedvat, Michael
    Moore, Gregory L.
    Desjarlais, John R.
    Kutlu, Olivia
    Erhardt, Joseph
    Philippar, Ulrike
    BLOOD, 2024, 144 : 1408 - 1409
  • [45] In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+B-cell lymphoma
    Timmerman, J.
    Betting, D.
    Yamada, R.
    Hurvitz, S.
    Steward, K.
    Said, J.
    van Rooijen, N.
    Kafi, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Novel CD123xCD3 bispecific IgM antibody, IGM-2537, potently induces T-cell mediated cytotoxicity of acute myeloid leukemia cells with minimal cytokine release
    Li, Gene
    Wang, Ling
    Yakkundi, Poonam
    Hinton, Paul
    Pandya, Deepal
    Sekar, Keerthana
    Rosete, Rodine
    Ye, Zhongde
    Hanna, Nardeen
    Kotturi, Maya F.
    Bogaert, Liz
    Hong, Jiyoung
    Tsai, Christina
    Manley, Thomas
    Keyt, Bruce A.
    Sinclair, Angus M.
    Liu, Liqin
    CANCER RESEARCH, 2023, 83 (07)
  • [47] Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20xCD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Matasar, Matthew
    Tucker, David
    Kim, Tae Min
    Luminari, Stefano
    Cheng, Yuan
    Li, Jingjin
    Shariff, Saleem
    Mohamed, Hesham
    Ambati, Srikanth
    Chaudhry, Aafia
    BLOOD, 2024, 144 : 3076 - 3077
  • [48] Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    Takei, K
    Yamazaki, T
    Sawada, U
    Ishizuka, H
    Aizawa, S
    LEUKEMIA RESEARCH, 2006, 30 (05) : 625 - 631
  • [49] High-Affinity CD20-Specific T-Cell Receptors Suitable for Adoptive Immunotherapy in the Treatment of CD20low B-Cell Malignancies
    Jahn, Lorenz
    Hombrink, Pleun
    Hassan, Chopie
    Kester, Michel G. D.
    Hagedoorn, Renate S.
    van der Steen, Dirk M.
    Schoonakker, Marjolein P.
    Falkenburg, J. H. Frederik
    van Veelen, Peter A.
    Heemskerk, Mirjam H. M.
    BLOOD, 2014, 124 (21)
  • [50] Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
    Liang, Zuyu
    Cui, Jiazhen
    Chang, Alex Hongsheng
    Yu, Jian
    Hu, Yongxian
    Huang, He
    REGENERATIVE THERAPY, 2020, 15 : 281 - 284
12345